Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA ODAC Supports CEL-SCI’s Multikine for PD-L1 Negative Cancer Patients
Details : Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, received Orphan Drug designation from the FDA for neoadjuvant therapy in squamous cell carcinoma of the head and neck.
Brand Name : Multikine
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 22, 2024
Lead Product(s) : Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : ThinkEquity
Deal Size : $10.8 million
Deal Type : Public Offering
CEL-SCI Announces Pricing of $10.8 Million Offering
Details : The proceeds will be used to advance the development of Multikine (leukocyte interleukin), which is being evaluated in the late-stage clinical trial studies for the treatment of head and neck cancer.
Brand Name : Multikine
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 26, 2024
Lead Product(s) : Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : ThinkEquity
Deal Size : $10.8 million
Deal Type : Public Offering
Lead Product(s) : Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CEL-SCI’s Phase 3 Analysis Demonstrates Balanced Patient Population for Head & Neck Cancer
Details : Multikine (leukocyte interleukin) injection which is designed to help the immune system target the tumor for the treatment of squamous cell carcinoma of the head and neck.
Brand Name : Multikine
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 26, 2024
Lead Product(s) : Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CEL-SCI Secures FDA Approval for Confirmatory Study of Multikine in Head & Neck Cancer
Details : Multikine (leukocyte interleukin) injection which is designed to help the immune system target the tumor for the treatment of squamous cell carcinoma of the head and neck.
Brand Name : Multikine
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 08, 2024
Lead Product(s) : Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : ThinkEquity
Deal Size : $7.7 million
Deal Type : Public Offering
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
Details : The net proceeds will used in the development of Multikine (leukocyte interleukin), which is designed to help the immune system target the tumor for squamous cell carcinoma of the head and neck.
Brand Name : Multikine
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 13, 2024
Lead Product(s) : Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : ThinkEquity
Deal Size : $7.7 million
Deal Type : Public Offering
Lead Product(s) : Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : ThinkEquity
Deal Size : $7.75 million
Deal Type : Public Offering
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
Details : The net proceeds will used in the development of Multikine (leukocyte interleukin), which is designed to help the immune system target the tumor for squamous cell carcinoma of the head and neck.
Brand Name : Multikine
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 09, 2024
Lead Product(s) : Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : ThinkEquity
Deal Size : $7.75 million
Deal Type : Public Offering
Lead Product(s) : Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : ThinkEquity
Deal Size : $5.0 million
Deal Type : Public Offering
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
Details : The Company intends to use the net proceeds to fund the continued development of Multikine (leukocyte interleukin, injection), an investigational immunotherapeutic agent being developed as a potential treatment for head and neck cancer, and cervical dysp...
Brand Name : Multikine
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 20, 2023
Lead Product(s) : Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : ThinkEquity
Deal Size : $5.0 million
Deal Type : Public Offering
Lead Product(s) : Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Multikine (Leukocyte Interleukin, Injection) immunotherapy to market for the treatment of newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Brand Name : Multikine
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 05, 2023
Lead Product(s) : Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Multikine (Leukocyte Interleukin, Injection) immunotherapy to market for the treatment of newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Brand Name : Multikine
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 26, 2023
Lead Product(s) : Leukocyte Interleukin,Cyclophosphamide,Indomethacin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Leukocyte Interleukin,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : ThinkEquity
Deal Size : $5.0 million
Deal Type : Public Offering
CEL-SCI Announces Closing of Public Offering
Details : The Company intends to use the proceeds to fund the continued development of Multikine (leukocyte interleukin, injection), an investigational immunotherapeutic agent being developed as a potential treatment for head and neck cancer, and cervical dysplasi...
Brand Name : Multikine
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 20, 2023
Lead Product(s) : Leukocyte Interleukin,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : ThinkEquity
Deal Size : $5.0 million
Deal Type : Public Offering
LOOKING FOR A SUPPLIER?